SORT BY Relevancy
This show is part of the Leukemia & Lymphoma Society Patient Education Series.
Our special guest is Dr. Christopher Yasenchak from Compass Oncology in Portland, Oregon. Dr. Yasenchak received his M.D. from Pennsylvania State University. He continued his training at the Mayo Clinic College of Medicine and is board certified in hematology, medical oncology and internal medicine. His clinical focus is multiple myeloma, lymphoma, stem cell transplantation, gastrointestinal malignancies and clinical trials.
Join host, Craig Lipset, Head of Clinical Innovation, R&D, Pfizer lead a discussion on Investing in the future of clinical research.
Todd Pietri, Co-Founder, Milestone Ventures
Jeremy Sohn, Managing Director, MPM Capital
VC views on:
Disruption in the clinical trial space
Finding opportunities (incubators and accelerators)
Good sources of deal flows
Investing in technology or people?
Beyond the pill
Craig, Todd and Jeremy will also be speaking at Mobile@Dpharm on September 10th at the Farimont Copley Plaza hotel in Boston. This event helps drug developers get their arms around the mobile/digital clinical trial landscape and figure out:
How mobile is innovating clinical trials
What parts of clinical trials mobile/digital technology is currently impacting
How mobile technology is making clinical trials cheaper, easier and more accurate
How mobile/digital is increasing the efficacy of drugs
What the true value is to clinical trials
There is an opportunity to participate in creating a clinical trial app. Mobile@Dpharm will also be of interest to investors and app developers. Following this one day event is DPharm: Disruptive Innovations to Advance Clinical Trials. For more information, visit www.theconferenceforum.org or call 646 350 2580.
In Clinical Air episode # 8, host Craig Lipset, Head of Clinical Innovation, R&D, Pfizer hosts a show discussing investigators as partners in clinical research. Guests include:
Christine Pierre, President, Society of Clinical Research
Jacalyn Kent, Director, Clinical Development Information & Optimization, Eli Lilly
Key topics include:
Misunderstandings around Remote Based Monitoring
Training and communication challenges for remote site managers
What are the real cost savings around RBM...are we just shifting costs?
Real time data and how this should affect sites and payments
Reducing burdens to the sites
Investigator turn over rate, making sites sustainable
Join host, Craig H. Lipset, Head of Clinical Innovation, R&D, Pfizer lead a discussion on what it really means to partner with patients in clinical trials.
Jeri Burtchell, Founder, Partners in Research
Regina Holliday, Artist and Medical Advocate
For more information on Jeri's new launch, visit: Healthivibe.com and for Regina walking gallary, google Regina Holliday, walking gallary.
For more information on the topic of Patients as Partners, visit www.theconferenceforum.org. The Conference Forum presented a program in March 2014 fully dedicated to understanding the journey a patient takes in clinical trials. Also take a look at Disruptive Innovations to Advance Clinical Trials scheduled for September 11-12, 2014 in Boston. This event addresses significant innovation to help improve a patients experience in a clinical trial.
Dr. Ian Thompson is Professor, Glenda and Gary Woods Distinguished Chair in GU Oncology at The University of Texas Health Science Center, San Antonio. Dr. Ian Thompson received his undergraduate degree from West Point and his M.D. degree from Tulane University. After a Residency in Urology in San Antonio, he completed a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center. Dr. Thompson has published over 400 scientific papers, several dozen book chapters, and has edited five textbooks in medicine and surgery. He currently serves as Vice-Chair of the Early Detection Research Network of the National Cancer Institute and is Chair of the Genitourinary Committee of the Southwest Oncology Group, the largest clinical trials organization supported by the National Cancer Institute. Dr. Thompson is the Principal Investigator of the San Antonio Center for Biomarkers Of Risk of Prostate Cancer. This cohort study, with up to 8 years of followup, currently follows over 3,600 men for development of prostate cancer and has been the source of many recent important developments in the early detection of prostate cancer.
Our prostate cancer panels are conducted in association with Prostate Cancer International and Prostate Cancer Foundation.
RSVP here (or) mail email@example.com
MIRAI CLINICAL | The Scent of Youth: Japan (March 24, 2014) - Mirai Clinical is introducing recent Japanese personal hygiene advances to the American market. It is common knowledge that an unpleasant odor is frequently noticed in nursing homes. This odor, sometimes referred to as "aging odor" or “old people smell”, has been incorrectly attributed to improper facilities cleaning, or incontinence and other ailments of the patients. The problem is particularly irksome in Japan, which has a culture of cleanliness. The minerals and water from our sweat are a fertile environment for bacterial growth, which is the source of traditional body odor noticed when we do not bathe adequately. Separately, the lipid acids we secrete "oxidize" with oxygen in the air, and transform into a different compound, which produces it's own odor. The researchers who discovered the phenomenon named the stale smelling compound "Nonenal (no-nay-nal)".
ABOUT MIRAI CLINICAL: Mirai Clinical Executive and Product Management is an International team comprised of experienced skin care and medical professionals from Japan and the U.S. Their mission is to develop the most ground-breaking, naturally safe and exceptionally effective products for body care and skin health. Mirai, which means “the future” or “new beginning,” issymbolic of this mission in introducing breakthrough, innovative skin care technology based on science and nature.Mirai Clinical Website: www.MiraiClinical.com
in Self Help
Michael Pellegrino is a Clinical Nutritionist specializing in Cancer Care. I will ask him about the aspects of helping someone being told to have Chemotherapy and Radiation...who would rather not. As most people today know, chemo and radiation kill off not only cancer cells but also the immune system, and other cells in the body. So Prevention being the best cure, we will address some of the toughest questions in this broadcast: How to recuperate from the dire circumstances of the last stages of cancer, and when it is found throughout the body?
With Love to you and Reverence for All Life, may something or most of what we say help you or someone you know and love!
Reverend Irene Windhorse
Allison Risha, RN, BSN, OCN, a nursing program coordinator from the Levine Cancer Institute in Charlotte, North Carolina, joins Mike and Joyce to talk about the current state of clinical trials for genitourinary cancers.
Ms. Risha has worked in many aspects of cancer treatment, and is currently a planner and organizer of programs for staff members and patients.
Please join us, and bring your own questions about clinical trials, what they offer beyond standard treatments, and what to think about when considering participation in a clinical trial.
Dr. Daniel Nightingale, or “Dr. Dan” is a leading UK Clinical Dementia Specialist now based in the US. He is also an author, writer and speaker, and a world leader in the use of hypnosis for people living with dementia. He runs workshops on Hypnosis for Alzheimer’s and Dementia with the help of his wife Kathleen Nightingale, a certified clinical hypnotherapist and Dementia Therapy Specialist.
He is concerned with developing new techniques for his patients based on their individual responses. One of Dr. Dan’s greatest strengths is to develop tailor made, individualized treatment plans to improve the quality of life of his patients.
Dr. Dan’s advice for up and coming hypnotists is to “Think outside the box. When I conducted research using hypnosis with dementia patients I had to break down many doors and barriers to get funding and ethical approval. However, I did it, and much to the amazement of cynics, I have been able to demonstrate that hypnosis can work for this cohort.”
You can learn more about Dr. Dan at www.dementiatherapyspecialists.com.
Dr. Dan Linked-In: https://www.linkedin.com/profile/view?id=159374846
Dr. Nightingale will be teaching and speaking at the Canadian Hypnosis Conference
We are very pleased to have Dr. Speid with us tonight. Lorna Speid, PhD, is a pharmacist. She works in the pharmaceutical industry as a regulatory affairs and drug development consultant. She has a practice in the development of new treatments for rare diseases.
After working for Sanofi Winthrop in the United Kingdom, Ciba Geigy at headquarters in Switzerland, and Novartis in Switzerland, she moved to the United States. She worked for three small companies in the United States, and now runs her own consulting practice. Dr. Speid sat on an important NIH Committee for the development of new treatments for rare diseases. She is the founder of a non-profit called Rare Diseases Patients First! This organization is planning to provide education to patients around the world that have a rare disease, about the clinical trial process. This will be done free of charge. We will provide more information about these educational internet-based meetings, as soon as they are ready to be rolled out later this year. Dr. Speid advises on the development of new treatments for rare diseases.
Dr. Speid saw a need to provide information to patients about clinical trials that would allow them to be empowered enough to ask the right questions before entering clinical trials, and while in clinical trials. She wrote the book Clinical Trials: What Patients and Healthy Volunteers Need to Know, to accomplish this. It was published by Oxford University Press in 2010.